Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea
In: Beneficial MicrobesSearch for other papers by E.C. Dinleyici in
Current site
Google Scholar
Search for other papers by A. Kara in
Current site
Google Scholar
Search for other papers by N. Dalgic in
Current site
Google Scholar
Search for other papers by Z. Kurugol in
Current site
Google Scholar
Search for other papers by V. Arica in
Current site
Google Scholar
Search for other papers by O. Metin in
Current site
Google Scholar
Search for other papers by E. Temur in
Current site
Google Scholar
Search for other papers by O. Turel in
Current site
Google Scholar
Search for other papers by S. Guven in
Current site
Google Scholar
Search for other papers by O. Yasa in
Current site
Google Scholar
Search for other papers by S. Bulut in
Current site
Google Scholar
Search for other papers by G. Tanir in
Current site
Google Scholar
Search for other papers by A.S. Yazar in
Current site
Google Scholar
Search for other papers by A. Karbuz in
Current site
Google Scholar
Search for other papers by M. Sancar in
Current site
Google Scholar
Search for other papers by M. Erguven in
Current site
Google Scholar
Search for other papers by G. Akca in
Current site
Google Scholar
Search for other papers by M. Eren in
Current site
Google Scholar
Search for other papers by M. Ozen in
Current site
Google Scholar
Search for other papers by Y. Vandenplas in
Current site
Google Scholar
Evidence from the literature has shown that Saccharomyces boulardii provides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact of S. boulardii CNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3rd day of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in the S. boulardii group (75.4±33.1 vs 99.8±32.5 h, P<0.001). The effect of S. boulardii (diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001, P<0.01 and P<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in the S. boulardii group (4.60±1.72 vs 6.12±1.71 days, P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20±0.4 vs 2.0±0.3 days, P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit of S. boulardii CNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Buts, J.P., 2009. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Digestive Diseases and Sciences 54: 15-18.
'Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives ' () 54 Digestive Diseases and Sciences : 15 -18.
-
Czerucka, D. and Rampal, P., 2002. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes and Infection 4: 733-739.
'Experimental effects of Saccharomyces boulardii on diarrheal pathogens ' () 4 Microbes and Infection : 733 -739.
-
Czerucka, D., Piche, T. and Rampal, P., 2007. Review article: yeast as probiotics –Saccharomyces boulardii. Alimentary Pharmacology and Therapeutics 26: 767-778.
'Review article: yeast as probiotics –Saccharomyces boulardii ' () 26 Alimentary Pharmacology and Therapeutics : 767 -778.
-
Dalgic, N., Sancar, M., Bayraktar, B., Pullu, M. and Hasim, O., 2011. Probiotic, zinc and lactose-free formula in children with rotavirus diarrhea: are they effective? Pediatrics International 53: 677-682.
'Probiotic, zinc and lactose-free formula in children with rotavirus diarrhea: are they effective? ' () 53 Pediatrics International : 677 -682.
-
Dinleyici, E.C., Eren, M., Ozen, M., Yargic, Z.A. and Vandenplas, Y., 2012. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opinion on Biological Therapy 12: 395-410.
'Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea ' () 12 Expert Opinion on Biological Therapy : 395 -410.
-
Dinleyici, E.C., Eren, M., Yargic, Z.A. and Vandenplas Y., 2011. Cost-effectiveness of add-on probiotics (Saccharomyces boulardii) in children with acute rotavirus diarrhea in Turkey (SB-cosTR). In: Proceedings of the 44th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition, 25-28 May, 2011 Sorrento, Italy, p. PO-G-0085.
'Cost-effectiveness of add-on probiotics (Saccharomyces boulardii) in children with acute rotavirus diarrhea in Turkey (SB-cosTR) ' , , .
-
Dinleyici, E.C., Kara, A., Ozen, M., and Vandenplas, Y., 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. Expert Opinion on Biological Therapy 14: 1593-1609.
'Saccharomyces boulardii CNCM I-745 in different clinical conditions ' () 14 Expert Opinion on Biological Therapy : 1593 -1609.
-
Floch, M.H, Walker, W.A., Madsen, K., Sanders, M.E., Macfarlane, G.T., Flint, H.J., Dieleman, L.A., Ringel, Y., Guandalini, S., Kelly, C.P. and Brandt, L.J., 2011. Recommendations for probiotic use – 2011 update. Journal of Clinical Gastroenterology 45 Suppl.: S168-S171.
'Recommendations for probiotic use – 2011 update ' () 45 Journal of Clinical Gastroenterology : S168 -S171.
-
Guarino, A., Ashkenazi, S., Gendrel, D., Vecchio, A.L., Shamir, R., Szajewska, H., 2014. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. Journal of Pediatric Gastroenterology and Nutrition 59: 132-152.
'European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014 ' () 59 Journal of Pediatric Gastroenterology and Nutrition : 132 -152.
-
Guarner, F., Khan, A.G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Lemair, T., Kaufmann, P., de Paula, J.A., Fedorak, R., Shanahan, F., Sanders, M.E., Szajewska, H., Ramakrishna, B.S., Karakan, T., and Kim, N., 2012. World Gastroenterology Organisation global guidelines: probiotics and probiotics. Journal of Clinical Gastroenterology 46: 468-481.
'World Gastroenterology Organisation global guidelines: probiotics and probiotics ' () 46 Journal of Clinical Gastroenterology : 468 -481.
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2013. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514.
'The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic ' () 11 Nature Reviews Gastroenterology and Hepatology : 506 -514.
-
Kelesidis, T. and Pothoulakis, C., 2012. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advance in Gastroenterology 5: 111-125.
'Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders ' () 5 Therapeutic Advance in Gastroenterology : 111 -125.
-
Kurugol, Z. and Koturoglu, G., 2005. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatrica 94: 44-47.
'Effects of Saccharomyces boulardii in children with acute diarrhoea ' () 94 Acta Paediatrica : 44 -47.
-
McFarland, L.V, 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology 16: 2202-2222.
'Systematic review and meta-analysis of Saccharomyces boulardii in adult patients ' () 16 World Journal of Gastroenterology : 2202 -2222.
-
Szajewska, H., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Shamir, R., Vandenplas, Y. and Weizman, Z., 2014. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. Journal of Pediatric Gastroenterololgy and Nutrition 58: 531-539.
'Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics ' () 58 Journal of Pediatric Gastroenterololgy and Nutrition : 531 -539.
-
Vandenplas, Y., Salvatore, S., Vieira, M., Devreker, T. and Hauser, B., 2007. Probiotics in infectious diarrhoea in children: are they indicated? European Journal of Pediatrics 166: 1211-1218.
'Probiotics in infectious diarrhoea in children: are they indicated? ' () 166 European Journal of Pediatrics : 1211 -1218.
-
Walker, C.L., Rudan, I., Liu, L., Nair, H., Theodoratou, E., Bhutta, Z.A., O’Brien, K.L., Campbell, H. and Black, R.E., 2013. Global burden of childhood pneumonia and diarrhoea. The Lancet 381: 1405-1416.
'Global burden of childhood pneumonia and diarrhoea ' () 381 The Lancet : 1405 -1416.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1094 | 333 | 28 |
| Full Text Views | 34 | 2 | 0 |
| PDF Views & Downloads | 43 | 6 | 0 |
Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea
In: Beneficial MicrobesSearch for other papers by E.C. Dinleyici in
Current site
Google Scholar
PubMed
Search for other papers by A. Kara in
Current site
Google Scholar
PubMed
Search for other papers by N. Dalgic in
Current site
Google Scholar
PubMed
Search for other papers by Z. Kurugol in
Current site
Google Scholar
PubMed
Search for other papers by V. Arica in
Current site
Google Scholar
PubMed
Search for other papers by O. Metin in
Current site
Google Scholar
PubMed
Search for other papers by E. Temur in
Current site
Google Scholar
PubMed
Search for other papers by O. Turel in
Current site
Google Scholar
PubMed
Search for other papers by S. Guven in
Current site
Google Scholar
PubMed
Search for other papers by O. Yasa in
Current site
Google Scholar
PubMed
Search for other papers by S. Bulut in
Current site
Google Scholar
PubMed
Search for other papers by G. Tanir in
Current site
Google Scholar
PubMed
Search for other papers by A.S. Yazar in
Current site
Google Scholar
PubMed
Search for other papers by A. Karbuz in
Current site
Google Scholar
PubMed
Search for other papers by M. Sancar in
Current site
Google Scholar
PubMed
Search for other papers by M. Erguven in
Current site
Google Scholar
PubMed
Search for other papers by G. Akca in
Current site
Google Scholar
PubMed
Search for other papers by M. Eren in
Current site
Google Scholar
PubMed
Search for other papers by M. Ozen in
Current site
Google Scholar
PubMed
Search for other papers by Y. Vandenplas in
Current site
Google Scholar
PubMed
Evidence from the literature has shown that Saccharomyces boulardii provides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact of S. boulardii CNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3rd day of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in the S. boulardii group (75.4±33.1 vs 99.8±32.5 h, P<0.001). The effect of S. boulardii (diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001, P<0.01 and P<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in the S. boulardii group (4.60±1.72 vs 6.12±1.71 days, P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20±0.4 vs 2.0±0.3 days, P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit of S. boulardii CNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1094 | 333 | 28 |
| Full Text Views | 34 | 2 | 0 |
| PDF Views & Downloads | 43 | 6 | 0 |
